Last10K.com

Actinium Pharmaceuticals, Inc. (ATNM) SEC Filing 10-Q Quarterly Report for the period ending Friday, September 30, 2022

SEC Filings

ATNM Quarterly Reports

Actinium Pharmaceuticals, Inc.

CIK: 1388320 Ticker: ATNM
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2022
Nov. 11, 2022
Document Information Line Items  
Entity Registrant NameACTINIUM PHARMACEUTICALS, INC. 
Trading SymbolATNM 
Document Type10-Q 
Current Fiscal Year End Date--12-31 
Entity Common Stock, Shares Outstanding 25,483,306
Amendment Flagfalse 
Entity Central Index Key0001388320 
Entity Current Reporting StatusYes 
Entity Filer CategoryNon-accelerated Filer 
Document Period End DateSep. 30, 2022 
Document Fiscal Year Focus2022 
Document Fiscal Period FocusQ3 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Entity File Number001-36374 
Entity Incorporation, State or Country CodeDE 
Entity Tax Identification Number74-2963609 
Entity Address, Address Line One275 Madison Ave, 7th Floor 
Entity Address, City or TownNew York 
Entity Address, State or ProvinceNY 
Entity Address, Postal Zip Code10016 
City Area Code(646) 
Local Phone Number677-3870 
Title of 12(b) SecurityCommon stock, par value $0.001 
Security Exchange NameNYSE 
Entity Interactive Data CurrentYes 

View differences made from one quarter to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actinium Pharmaceuticals, Inc..

Continue

Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Cash Flow
Geography
Shares
Other
Inside Actinium Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parentheticals)
Condensed Consolidated Statement Of Changes In Stockholders??? Equity (Unaudited)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited) (Parentheticals)
Accounting Policies, By Policy (Policies)
Commitments And Contingencies
Commitments And Contingencies (Details)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (Details)
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Cash, Cash Equivalents And Restricted Cash
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Diluted Net Loss Per Share Anti-Dilutive
Description Of Business And Summary Of Significant Accounting Policies (Tables)
Equity
Equity (Details) - Schedule Of Stock Option Activity
Equity (Details) - Schedule Of Warrant Activities
Equity (Details)
Equity (Tables)
Leases
Leases (Details)
Leases (Details) - Schedule Of Components Of Lease Expense
Leases (Details) - Schedule Of Maturities Of Lease Liabilities
Leases (Details) - Schedule Of Supplemental Cash Flow Information Related To Leases
Leases (Details) - Schedule Of Weighted Average Discount Rates
Leases (Details) - Schedule Of Weighted Average Remaining Lease Terms
Leases (Tables)
Other Revenue
Other Revenue (Details)
Subsequent Event
Subsequent Event (Details)

Material Contracts, Statements, Certifications & more

Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ATNM
CIK: 1388320
Form Type: 10-Q Quarterly Report
Accession Number: 0001213900-22-072371
Submitted to the SEC: Mon Nov 14 2022 5:01:20 PM EST
Accepted by the SEC: Mon Nov 14 2022
Period: Friday, September 30, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/atnm/0001213900-22-072371.htm